AbbVie Inc.
ABBV
$195.22
$6.203.28%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 57.37B | 56.33B | 55.53B | 55.00B | 54.40B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.37B | 56.33B | 55.53B | 55.00B | 54.40B |
| Cost of Revenue | 16.81B | 16.87B | 16.65B | 16.81B | 16.82B |
| Gross Profit | 40.56B | 39.47B | 38.88B | 38.19B | 37.59B |
| SG&A Expenses | 13.41B | 13.25B | 13.92B | 13.19B | 13.03B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -7.00M | -7.00M | 169.00M | 169.00M | 0.00 |
| Total Operating Expenses | 38.59B | 38.24B | 38.50B | 37.58B | 37.04B |
| Operating Income | 18.78B | 18.09B | 17.03B | 17.42B | 17.37B |
| Income Before Tax | 3.62B | 3.72B | 7.20B | 7.07B | 7.53B |
| Income Tax Expenses | -581.00M | -570.00M | 2.06B | 1.72B | 1.53B |
| Earnings from Continuing Operations | 4.20K | 4.29K | 5.13K | 5.35K | 6.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -8.00M | -8.00M | -11.00M | -11.00M | -11.00M |
| Net Income | 4.20B | 4.28B | 5.12B | 5.34B | 5.99B |
| EBIT | 18.78B | 18.09B | 17.03B | 17.42B | 17.37B |
| EBITDA | 27.13B | 26.48B | 25.39B | 25.94B | 26.01B |
| EPS Basic | 2.35 | 2.40 | 2.87 | 3.00 | 3.37 |
| Normalized Basic EPS | 5.92 | 5.74 | 5.43 | 5.58 | 5.58 |
| EPS Diluted | 2.35 | 2.40 | 2.87 | 3.00 | 3.37 |
| Normalized Diluted EPS | 5.91 | 5.73 | 5.43 | 5.57 | 5.57 |
| Average Basic Shares Outstanding | 7.07B | 7.08B | 7.08B | 7.08B | 7.08B |
| Average Diluted Shares Outstanding | 7.08B | 7.09B | 7.09B | 7.09B | 7.09B |
| Dividend Per Share | 6.38 | 6.29 | 6.20 | 6.13 | 6.06 |
| Payout Ratio | 266.46% | 257.71% | 212.79% | 201.82% | 177.71% |